Risk of systemic reactions in patients taking beta-blocker drugs receiving allergen immunotherapy injections

M. J. Hepner; D. R. Ownby; J. A. Anderson; M. S. Rowe; D. Sears-Ewald; E. B. Brown

doi:10.1016/S0091-6749(05)80105-8

Risk of systemic reactions in patients taking beta-blocker drugs receiving allergen immunotherapy injections

M. J. Hepner, D. R. Ownby, J. A. Anderson, M. S. Rowe, D. Sears-Ewald, E. B. Brown

Research output: Contribution to journal › Article › peer-review

95 Scopus citations

Abstract

To learn whether patients taking beta-blocker (BB) drugs were at increased risk of having systemic reactions (SRs) from allergen immunotherapy, we prospectively studied 56,105 injection visits in 3178 patients during a 1-year interval. A total of 166 SRs occurred in 144 patients (4.5% of all patients) or 3.0 SRs occurred per 1000 injection visits. Sixty-eight patients were taking BB drugs throughout the year, and only one patient had an SR. By chance, 3.08 patients were expected to have had SRs. We conclude that BB drugs did not increase the frequency of SRs in teh patients studied who were receiving immunotherapy (p>0.95). Patients taking BB drugs may still be at increased risk, however, from more severe SRs or their SRs may be more refractory to therapy.

Original language	English (US)
Pages (from-to)	407-411
Number of pages	5
Journal	The Journal of Allergy and Clinical Immunology
Volume	86
Issue number	3 PART 1
DOIs	https://doi.org/10.1016/S0091-6749(05)80105-8
State	Published - Sep 1990
Externally published	Yes

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1016/S0091-6749(05)80105-8

Cite this

@article{25a422a38c2348dc8ae194fef2d3d787,

title = "Risk of systemic reactions in patients taking beta-blocker drugs receiving allergen immunotherapy injections",

abstract = "To learn whether patients taking beta-blocker (BB) drugs were at increased risk of having systemic reactions (SRs) from allergen immunotherapy, we prospectively studied 56,105 injection visits in 3178 patients during a 1-year interval. A total of 166 SRs occurred in 144 patients (4.5% of all patients) or 3.0 SRs occurred per 1000 injection visits. Sixty-eight patients were taking BB drugs throughout the year, and only one patient had an SR. By chance, 3.08 patients were expected to have had SRs. We conclude that BB drugs did not increase the frequency of SRs in teh patients studied who were receiving immunotherapy (p>0.95). Patients taking BB drugs may still be at increased risk, however, from more severe SRs or their SRs may be more refractory to therapy.",

author = "Hepner, {M. J.} and Ownby, {D. R.} and Anderson, {J. A.} and Rowe, {M. S.} and D. Sears-Ewald and Brown, {E. B.}",

year = "1990",

month = sep,

doi = "10.1016/S0091-6749(05)80105-8",

language = "English (US)",

volume = "86",

pages = "407--411",

journal = "The Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Mosby Inc.",

number = "3 PART 1",

}

TY - JOUR

T1 - Risk of systemic reactions in patients taking beta-blocker drugs receiving allergen immunotherapy injections

AU - Hepner, M. J.

AU - Ownby, D. R.

AU - Anderson, J. A.

AU - Rowe, M. S.

AU - Sears-Ewald, D.

AU - Brown, E. B.

PY - 1990/9

Y1 - 1990/9

N2 - To learn whether patients taking beta-blocker (BB) drugs were at increased risk of having systemic reactions (SRs) from allergen immunotherapy, we prospectively studied 56,105 injection visits in 3178 patients during a 1-year interval. A total of 166 SRs occurred in 144 patients (4.5% of all patients) or 3.0 SRs occurred per 1000 injection visits. Sixty-eight patients were taking BB drugs throughout the year, and only one patient had an SR. By chance, 3.08 patients were expected to have had SRs. We conclude that BB drugs did not increase the frequency of SRs in teh patients studied who were receiving immunotherapy (p>0.95). Patients taking BB drugs may still be at increased risk, however, from more severe SRs or their SRs may be more refractory to therapy.

AB - To learn whether patients taking beta-blocker (BB) drugs were at increased risk of having systemic reactions (SRs) from allergen immunotherapy, we prospectively studied 56,105 injection visits in 3178 patients during a 1-year interval. A total of 166 SRs occurred in 144 patients (4.5% of all patients) or 3.0 SRs occurred per 1000 injection visits. Sixty-eight patients were taking BB drugs throughout the year, and only one patient had an SR. By chance, 3.08 patients were expected to have had SRs. We conclude that BB drugs did not increase the frequency of SRs in teh patients studied who were receiving immunotherapy (p>0.95). Patients taking BB drugs may still be at increased risk, however, from more severe SRs or their SRs may be more refractory to therapy.

UR - http://www.scopus.com/inward/record.url?scp=0024995754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024995754&partnerID=8YFLogxK

U2 - 10.1016/S0091-6749(05)80105-8

DO - 10.1016/S0091-6749(05)80105-8

M3 - Article

C2 - 1976666

AN - SCOPUS:0024995754

SN - 0091-6749

VL - 86

SP - 407

EP - 411

JO - The Journal of Allergy and Clinical Immunology

JF - The Journal of Allergy and Clinical Immunology

IS - 3 PART 1

ER -

Risk of systemic reactions in patients taking beta-blocker drugs receiving allergen immunotherapy injections

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this